Cibc World Markets Corp Purchases Shares of 17,760 Hims & Hers Health, Inc. (NYSE:HIMS)

Cibc World Markets Corp purchased a new stake in Hims & Hers Health, Inc. (NYSE:HIMS) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 17,760 shares of the company’s stock, valued at approximately $429,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of HIMS. SlateStone Wealth LLC grew its holdings in shares of Hims & Hers Health by 4.0% during the fourth quarter. SlateStone Wealth LLC now owns 10,640 shares of the company’s stock valued at $257,000 after buying an additional 413 shares during the last quarter. Harbour Investments Inc. grew its holdings in shares of Hims & Hers Health by 18.8% during the fourth quarter. Harbour Investments Inc. now owns 5,269 shares of the company’s stock valued at $127,000 after buying an additional 833 shares during the last quarter. Natixis Advisors LLC acquired a new position in shares of Hims & Hers Health during the fourth quarter valued at about $617,000. Blume Capital Management Inc. grew its holdings in shares of Hims & Hers Health by 100.0% during the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after buying an additional 600 shares during the last quarter. Finally, Atala Financial Inc acquired a new position in shares of Hims & Hers Health during the fourth quarter valued at about $152,000. 63.52% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, insider Soleil Boughton sold 4,152 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total value of $251,984.88. Following the sale, the insider now owns 157,345 shares of the company’s stock, valued at $9,549,268.05. The trade was a 2.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Michael Chi sold 7,259 shares of the business’s stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $24.07, for a total transaction of $174,724.13. Following the completion of the sale, the insider now directly owns 193,601 shares in the company, valued at approximately $4,659,976.07. This trade represents a 3.61 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,015,547 shares of company stock valued at $36,146,450. Company insiders own 17.71% of the company’s stock.

Hims & Hers Health Stock Performance

Shares of HIMS stock opened at $34.77 on Monday. The firm has a market cap of $7.72 billion, a price-to-earnings ratio of 79.02 and a beta of 1.37. Hims & Hers Health, Inc. has a 52 week low of $11.20 and a 52 week high of $72.98. The firm’s 50-day simple moving average is $39.21 and its two-hundred day simple moving average is $28.89.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, February 24th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.09 by $0.02. The business had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. Analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on HIMS. Needham & Company LLC lifted their price objective on shares of Hims & Hers Health from $31.00 to $61.00 and gave the company a “buy” rating in a report on Tuesday, February 25th. Leerink Partners lifted their price objective on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a report on Tuesday, February 25th. Citigroup restated a “sell” rating and set a $27.00 price target on shares of Hims & Hers Health in a report on Thursday, March 6th. Morgan Stanley cut shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and boosted their price target for the stock from $42.00 to $60.00 in a report on Tuesday, February 18th. Finally, Bank of America boosted their price target on shares of Hims & Hers Health from $21.00 to $22.00 and gave the stock an “underperform” rating in a report on Tuesday, March 18th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, Hims & Hers Health has a consensus rating of “Hold” and an average target price of $37.31.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.